Reports of recent clinical trial data from ASCO 2012
has established survival benefit in patients
with mCRPC who have been treated with docetaxel.
is the first randomized trial to demonstrate
both OS and rPFS benefits in chemo-naive mCRPC
and to show that inhibition of persistent
extragonadal androgen synthesis significantly
delays initiation of cytotoxic CT.
was not reached in the abiraterone arm; the
median OS in the placebo arm (27.2 months)
is the longest measured in any Phase III mCRPC
determine the OS benefit of abiraterone in
patients with progressive mCRPC not yet treated